Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
RLAY
SELLRelay Therapeutics, Inc. · Healthcare · United States · $4.0B · Avg Vol: $72M/d
COMPANY DESCRIPTION
Relay Therapeutics, Inc. is a clinical-stage precision medicine company focused on transforming drug discovery through its proprietary Dynamo platform. The company's competitive moat lies in its ability to integrate computational and experimental technologies to analyze protein motion, enabling the targeting of previously undruggable disease drivers. It operates as a leading-edge biotechnology innovator specializing in precision oncology and genetic diseases.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.4M | 25.5M | 10.0M | 15.4M | 123.2% | 10.7M | 11.8M | 14.5M | -2.8% |
| EPS | -2.59 | -2.79 | -2.36 | -1.61 | — | -1.50 | -1.53 | -1.64 | — |
| Shares | 121.1M | 127.5M | 167.8M | 173.9M | +43.6% | 217.9M | — | — | — |
| Debt | 57.7M | 53.5M | 48.5M | 32.5M | -17.5% | 31.6M | — | — | — |
| Equity | 950.2M | 752.0M | 777.8M | 567.1M | -15.8% | — | — | — | — |
| Op CF | -229.5M | -300.3M | -249.1M | -235.5M | — | -213.4M | — | — | — |
| Inv CF | -188.7M | 257.6M | -41.1M | 192.8M | — | — | — | — | — |
| Fin CF | 289.9M | 34.8M | 270.2M | 1.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RLAY are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| RLAY | Relay Therapeutics, Inc.(you) | $4.0B | 32 | SELL |
| EWTX | Edgewise Therapeutics, Inc. | $4.4B | 30 | SELL |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.4B | 32 | SELL |
| DYN | Dyne Therapeutics, Inc. | $4.0B | 35 | HOLD |
| TNGX | Tango Therapeutics, Inc. | $4.3B | 29 | SELL |
| IDYA | IDEAYA Biosciences, Inc. | $3.4B | 29 | SELL |
| CAI | Caris Life Sciences, Inc. | $4.4B | 27 | SELL |
| DNLI | Denali Therapeutics Inc. | $3.7B | 26 | SELL |
| LEGN | Legend Biotech Corporation | $4.3B | 24 | SELL |
| ATAI | AtaiBeckley Inc. | $2.7B | 31 | SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.6%